{
    "clinical_study": {
        "@rank": "121005", 
        "arm_group": [
            {
                "arm_group_label": "Cases", 
                "description": "Infants with culture confirmed GBS disease"
            }, 
            {
                "arm_group_label": "Controls", 
                "description": "Infants born to GBS colonized mother who do not develop GBS disease"
            }
        ], 
        "biospec_descr": {
            "textblock": "Maternal and cord serum aliquots will be retained."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Feasibility phase for a study to evaluate antibody levels against Group B Streptococcus in\n      mothers and their infants at delivery to establish antibody levels associated with\n      reductions in risk of GBS disease in infants aged less than 90 days."
        }, 
        "brief_title": "Feasibility Study Identifying Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Young Infants.", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Invasive Group B Streptococcus Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        (i) Pregnant women attending antenatal clinic in one of the participating\n        antenatal-clinics and/or delivering at one the participating delivery center.\n\n        (ii) Subjects aged \u226518 years. (iii)  Able to understand and comply with planned study\n        procedures. (iv) Provides written informed consent.\n\n        Exclusion Criteria:\n\n        (i) Refuses to consent to study participation."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pregnant women aged 18 years or older attending for antenatal care or delivery at 1\n        academic hospital centers in the Johannesburg area and the antenatal clinics serving that\n        hospital centers."
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888471", 
            "org_study_id": "V98_22OB"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Feasibility", 
            "Group B Streptococcus", 
            "anti-capsular antibodies", 
            "serotype specific"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "last_name": "Shabir Madhi, Professor"
            }, 
            "facility": {
                "address": {
                    "city": "Soweto", 
                    "country": "South Africa", 
                    "state": "Gauteng", 
                    "zip": "2013"
                }, 
                "name": "Respiratory and Meningeal Pathogen Research Unit"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_groups": "2", 
        "official_title": "Feasibility Study for Identifying a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.", 
        "overall_contact": {
            "last_name": "Novartis Drug Information Services", 
            "phone": "18002447668"
        }, 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines and Diagnostics", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South African: South African Medicines Control Council", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To test key operational aspects of the proposed nested case control study to identify antibody levels associated with reduced risk of GBS disease in infants", 
                "measure": "Enrolment rates", 
                "safety_issue": "No", 
                "time_frame": "Throughout the study"
            }, 
            {
                "measure": "Completeness of clinical data collection", 
                "safety_issue": "No", 
                "time_frame": "Throughout the study"
            }, 
            {
                "measure": "Proposition maternal-infant dyads with maternal and cord collected.", 
                "safety_issue": "No", 
                "time_frame": "Throughout the study"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888471"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Provide baseline population data on maternal GBS serotype distribution and anticapsular antibody levels", 
                "measure": "GBS serotype distribution in subjects vaginally colonized with GBS at delivery.", 
                "safety_issue": "No", 
                "time_frame": "Throughout the study"
            }, 
            {
                "measure": "Distribution of GBS anticapsular antibody concentrations (ser in subjects vaginally colonized with GBS at delivery.", 
                "safety_issue": "No", 
                "time_frame": "Throughout the study"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}